All In Biotech

Drug Trial Radar · NCT02195817

Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

Interventional, Open-label Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

Last checked: Nov 20, 2026Latest source record: Feb 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

378

Actual

Start

Aug 2014

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Jul 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the reduction in alcohol consumption in patients with alcohol dependence treated with 18 mg Selincro® as-needed use, in conjunction with continuous psychosocial support in primary care

Conditions

  • Alcohol Dependence

Interventions

  • Selincro® 18 mg with continuous psychosocial support: Cohort ADrug

  • Initial psychosocial support: Cohort BOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the number of Heavy Drinking Days (HDDs) (days/month)Time frame: Baseline to Month 3

Locations

48 sites in 4 countries. Site status is shown where the registry gives one.

  • FR010

    Bécon-les-Granits, France

  • FR001

    Bordeaux, France

  • FR005

    Bordeaux, France

  • FR009

    Cestas, France

  • FR012

    Chauny, France

  • FR002

    Coulounieix-Chamiers, France

  • FR008

    La Teste-de-Buch, France

  • FR007

    Mont-de-Marsan, France

  • FR011

    Narbonne, France

  • FR003

    Targon, France

  • FR006

    Tonneins, France

  • FR004

    Vieux-Boucau-les-Bains, France

  • DE002

    Berlin, Germany

  • DE005

    Berlin, Germany

  • DE006

    Essen, Germany

  • DE003

    Jahnsdorf, Germany

  • DE004

    Jahnsdorf, Germany

  • DE011

    Mannheim, Germany

  • DE009

    Nuremberg, Germany

  • DE010

    Offenbach, Germany

  • DE001

    Wallerfing, Germany

  • DE007

    Weilburg, Germany

  • DE008

    Weinheim, Germany

  • ES001

    Badalona, Spain

  • ES010

    Badalona, Spain

  • ES003

    Barcelona, Spain

  • ES004

    Barcelona, Spain

  • ES008

    Canet de Mar, Spain

  • ES007

    el Prat de Llobregat, Spain

  • ES006

    Hospitalet Del Llobregat, Spain

  • ES009

    Hospitalet Del Llobregat, Spain

  • ES011

    Hospitalet Del Llobregat, Spain

  • ES013

    Matar, Spain

  • ES002

    Mataró, Spain

  • ES012

    Sabadell, Spain

  • ES005

    Tarragona, Spain

  • GB011

    Ballymena, United Kingdom

  • GB008

    Belfast, United Kingdom

  • GB009

    Belfast, United Kingdom

  • GB004

    Cardiff, United Kingdom

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.